Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2′-deoxyuridine

Investigational New Drugs

Volumn 29, Issue 2, 2011, Pages 248-257

  Bijnsdorp, Irene V ^a   Schwendener, Reto A ^b   Schott, Herbert ^c   Fichtner, Iduna ^d   Smid, Kees ^a   Laan, Adrie C ^a   Schott, Sarah ^a   Losekoot, Nienke ^a   Honeywell, Richard J ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

5 fluoro 2 deoxyuridine; Duplex drug; Ethynylcytidine; Multidrug; Prodrugs

Indexed keywords

3' ETHYNYLCYTIDINE; FLOXURIDINE; FLUOROURACIL; LIPOSOME; NUCLEOSIDE; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; 1 (3 C ETHYNYLRIBOPENTOFURANOSYL)CYTOSINE; 1-(3-C-ETHYNYLRIBOPENTOFURANOSYL)CYTOSINE; CYTIDINE; DRUG DERIVATIVE; FLOXURIDINE PHOSPHATE; NUCLEOSIDE TRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DIVISION; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; EXTRACELLULAR SPACE; HUMAN; IC 50; METABOLISM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYTIDINE; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SPACE; FLOXURIDINE; FLUORODEOXYURIDYLATE; HUMANS; INHIBITORY CONCENTRATION 50; LIPOSOMES; MICE; NUCLEOSIDE TRANSPORT PROTEINS; NUCLEOSIDES; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79957503358     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-009-9353-2     Document Type: Article

References (48)

1. van Laar JA, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ (1998) Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 34:296-306 (Pubitemid 28183825)
2. Köhne CH, Peters GJ (2000) UFT: mechanism of drug action. Oncology (Williston Park) 14:13-18
3. Folprecht G, Köhne CH (2005) Drug Insight: Metastatic colorectal cancer-oral fluoropyrimidines and new perspectives in the adjuvant setting. Nat Clin Pract Oncol 2:578-587 (Pubitemid 41721817)
4. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci- Pisanelli G, van der Wilt CL et al (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587:194-205 (Pubitemid 34655788)
5. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larráyoz I, Martínez-Picado J (2005) Cell entry and export of nucleoside analogues. Virus Res 107:151-164 (Pubitemid 40093088)
6. Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML et al (2004) Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 67:503-511 (Pubitemid 38232890)
7. Galmarini CM, Popowycz F, Joseph B (2008) Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. Curr Med Chem 15:1072-1082 (Pubitemid 352002976)
8. Adema AD, Bijnsdorp IV, Sandvold ML, Verheul HM, Peters GJ (2009) Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer. Cur Med Chem 16:4632-4643
9. Peyrottes S, Egron D, Lefebvre I, Gosselin G, Imbach JL, Périgaud C (2004) SATE pronucleotide approaches: an overview. Mini Rev Med Chem 4:395-408 (Pubitemid 38842602)
10. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87:227-253
11. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947 (Pubitemid 30644117)
12. Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European organisation for research and treatment of cancer gastrointestinal group study 40986. J Clin Oncol 23:4856-4865 (Pubitemid 46223990)
13. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al (2000) Irinotecan combined with Fluorouracil compared with Fluorouracil alone as First-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041-1047 (Pubitemid 30162806)
14. McElhinney RS, McCormick JE, Bibby MC, Double JA, Atassi G, Dumont P et al (1989) Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions. Anticancer Drug Des 3:255-269 (Pubitemid 19100903)
15. Naito T, Yokogawa T, Kim HS, Futagami M, Wataya Y, Matsuda A, et al (2002) Anticancer mechanisms of 1-(3-C-ethynyl-beta-Dribo- pentofuranosyl) cytosine (ECyd, TAS-106). Nucleic Acids Res Suppl (2):241-2
16. Hattori H, Tanaka M, Fukushima M, Sasaki T, Matsuda A (1996) Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta- D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribopentofuranosyl) uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Med Chem 39:5005-5011 (Pubitemid 26422516)
17. Shimamoto Y, Kazuno H, Murakami Y, Azuma A, Koizumi K, Matsuda A et al (2002) Cellular and biochemical mechanisms of the resistance of human cancer cells to a new anticancer ribo-nucleoside, TAS-106. Jpn J Cancer Res 93:445-452 (Pubitemid 34506255)
18. Saiko P, Horvath Z, Illmer C, Madlener S, Bauer W, Hoechtl T et al (2005) Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells. Leuk Res 29:785-791 (Pubitemid 40779485)
19. Bijnsdorp IV, Schwendener RA, Schott H, Fichtner I, Smid K, Schott S et al (2007) In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine. Nucleosides Nucleotides Nucleic Acids 26:1619-1624 (Pubitemid 350240793)
20. Phuphanich S, Maria B, Braeckman R, Chamberlain M (2007) A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 81:201-208 (Pubitemid 44963980)
21. O'Shaughnessy JA (2003) Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 4:318-328 (Pubitemid 38139586)
22. Schwendener RA (2007) Liposomes in biology and medicine. Adv Exp Med Biol 620:117-128
23. Schott H, Schott S, Schwendener RA (2009) Synthesis and in vitro activities of new anticancer duplex drugs linking 2′-deoxy- 5-fluorouridine (5-FdU) with 3′-C-ethynylcytidine (ECyd) via a phosphodiester bonding. Bioorg Med Chem 17:6824-6831
24. Balzarini J, de Clercq E, Ayusawa D, Seno T (1985) Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5- (2-bromovinyl)-2′-deoxyuridine and related compounds. FEBS Lett 185:95-100 (Pubitemid 15058193)
25. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27:897-900
26. Wu W, Sigmond J, Peters GJ, Borch RF (2007) Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J Med Chem 50:3743-3746 (Pubitemid 47195480)
27. Peters GJ, Laurensse E, Leyva A, Lankelma J, Pinedo HM (1986) Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′- deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46:20-28 (Pubitemid 16189022)
28. Rots MG, Pieters R, Kaspers GJL, van Zantwijk CH, Noordhuis P, Mauritz R et al (1999) Differential methotrexate resistance in childhood T- versus Common/PreB-Acute lymphoblastic Leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood 93:1067-1074 (Pubitemid 29067873)
29. van Triest B, Pinedo HM, Telleman F, van der Wilt CL, Jansen G, Peters GJ (1997) Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. Biochem Pharmacol 53:1855-1866 (Pubitemid 27356058)
30. Spears CP, Gustavsson BG, Berne M, Frösing R, Bernstein L, Hayes AA (1988) Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 48:5894-5900
31. van der Wilt CL, van Laar JA, Smid K, Rustum YM, Peters GJ (1994) Comparison of 5-fluoro-2′-deoxyuridine and 5-fluorouracil in the treatment of murine colon cancer; effects on thymidylate synthase. Adv Exp Med Biol 370:109-114
32. Laurensse EJ, Pinedo HM, Peters GJ (1988) A sensitive non-radioactive assay for pyrimidine nucleoside phosphorylase using reversed-phase high performance liquid chromatography. Clin Chim Acta 178:71-78
33. Honeywell R, Laan AC, van Groeningen CJ, Strocchi E, Ruiter R, Giaccone G et al (2007) The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 847:142-152 (Pubitemid 46331023)
34. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T et al (2004) Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40:298-307 (Pubitemid 38077034)
35. Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J (2004) Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 18:385-393 (Pubitemid 38425849)
36. Huber-Ruano I, Pastor-Anglada M (2009) Transport of nucleoside analogs across the plasma membrane: a clue to understanding drug-induced cytotoxicity. Curr Drug Metab 10:347-358
37. van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS et al (1999) Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 5:643-654 (Pubitemid 29131976)
38. Serova M, Galmarini CM, Ghoul A, Benhadji K, Green SR, Chiao J et al (2007) Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells. Br J Cancer 97:628-636 (Pubitemid 47339878)
39. Horber DH, Cattaneo-Pangrazzi RM, von Ballmoos P, Schott H, Ludwig PS, Eriksson S et al (2000) Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl- (5′->5′)- N4-octadecyl-1-beta-D-arabinofuranosylcytosine. J Cancer Res Clin Oncol 126:311-319 (Pubitemid 30349568)
40. Breistøl K, Balzarini J, Sandvold ML, Myhren F, Martinsen M, De Clercq E et al (1999) Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res 59:2944-2949 (Pubitemid 29283136)
41. Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML et al (2004) antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 67:503-511 (Pubitemid 38232890)
42. Bijnsdorp IV, Comijn EM, Padron JM, Gmeiner WH, Peters GJ (2007) Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Oncol Rep 18:287-291
43. Gmeiner WH, Trump E, Wei C (2004) Enhanced DNA-directed effects of FdUMP[10] compared to 5FU. Nucleosides Nucleotides Nucleic Acids 23:401-410 (Pubitemid 38351988)
44. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992 (Pubitemid 24085451)
45. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA (1999) Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in longcirculating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1-7 (Pubitemid 29048341)
46. Minko T, Pakunlu RI, Wang Y, Khandare JJ, Saad M (2006) New generation of liposomal drugs for cancer. Anticancer Agents Med Chem 6:537-552 (Pubitemid 44697112)
47. Béduneau A, Saulnier P, Benoit JP (2007) Active targeting of brain tumors using nanocarriers; Biomaterials 28:4947-4967 (Pubitemid 47362345)
48. Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL, Pinedo HM (2000) Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 36:916-924 (Pubitemid 30214143)